Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPER: Cyclophosphamide + Pembrolizumab in RCC
NCT04262427Phase 2Unknown
- Sponsor
- The Christie
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by The Christie. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
cyclophosphamidepembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04262427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262427.